




>>Entry Name: Teniposide, BAN, INN, USAN

Synonym(s): 9-(4,6-O-2-Thienylidene-β-D-glucopyranoside)-4'-demethylepipodophyllotoxin, 8Cl. Vumon. EPT. NSC 122819. Vehem-Sanoloz. VM 26



CAS Registry Number: 29767-20-2

Related CAS Registry Numbers(s): 89301-94-0

Molecular Formula: C₃₂H₃₂O₁₃S

Molecular Weight: 656.663

Accurate Mass: 656.156365

Percentage Composition: C 58.53%; H 4.91%; O 31.67%; S 4.88%

Use/Importance: DNA topoisomerase II inhibitor. Antineoplastic agent. Used in combination therapies

Physical Description: Cryst. (EtOH)

Melting Point: Mp 242-246°

Optical Rotation: $[\alpha]_D^{20} -107$ (CHCl₃/MeOH)

Calculated Log P Data: Log P -0.75 (uncertain value) (calc)

Hazard & Toxicity: Adverse haemopoietic and other effects when used therapeutically. LD₅₀ (mus, ipr) 29.6 mg/kg. Exp. reprod. and teratogenic effects

References:

- Stähelin, H., *Eur. J. Cancer*, 1970, **6**, 303, (pharmacol)
U.S. Pat., 1970, Sandoz, 3 524 844; CA, **70**, 78340a, (synth)
Allen, L., *Drug Metab. Rev.*, 1978, **8**, 119, (rev, metab)
Issell, B.F., *Cancer Chemother. Pharmacol.*, 1982, **7**, 73; 87; 93; 133
Kettenes-van den Bosch, J.J. et al., *Anal. Profiles Drug Subst.*, 1990, **19**, 575, (rev)
Stähelin, H.F. et al., *Cancer Res.*, 1991, **51**, 5, (rev)
Semin. Oncol., Suppl 6, 1992, **19**, 1-102, (rev)
Cragg, G. et al., *Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents*, (ed. Powis, G.), Pergamon Press, 1994, 364, (rev)
Martindale, *The Extra Pharmacopoeia*, 31st edn., Pharmaceutical Press, 1996, 602
Andreassen, P.R. et al., *J. Cell Biol.*, 1997, **136**, 29, (pharmacol)
Lewis, R.J., *Sax's Dangerous Properties of Industrial Materials*, 8th edn., Van Nostrand Reinhold, 1992, EQP000